|
- Tolebrutinib: What is it and is it FDA approved? - Drugs. com
Current FDA approval status, regulatory history, and clinical trial results for tolebrutinib, an investigational treatment for non-relapsing secondary progressive multiple sclerosis from the development pipeline at Sanofi
- Sanofis tolebrutinib cuts MS progression by 31% in trial
Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple . . .
Tolebrutinib is an oral, brain-penetrant Bruton’s tyrosine kinase inhibitor that targets myeloid cells (including microglia) and B cells in both the periphery and central nervous system There
- FDA Breakthrough Therapy Tolebrutinib | National MS Society
Sanofi, Inc has announced that tolebrutinib — an experimental, oral BTK-inhibitor — has been designated by the U S Food and Drug Administration as a “Breakthrough Therapy” for treatment of non-relapsing secondary progressive MS
- Tolebrutinib - MS Trust
Tolebrutinib is a new drug treatment under investigation for secondary progressive and primary progressive multiple sclerosis (MS) It is taken as a tablet once daily
- Press Release: Tolebrutinib designated Breakthrough Therapy . . .
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS)
- Safety and efficacy of tolebrutinib, an oral brain-penetrant . . .
Tolebrutinib is an oral, central nervous system–penetrant, irreversible inhibitor of Bruton’s tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells (including microglia), which are major drivers of inflammation in multiple sclerosis (MS)
|
|
|